MARKETS
Earnings

Organogenesis Hldgs Q2 Adj. EPS $(0.69) Misses $(0.35) Estimate, Sales $100.779M Beat $54.250M Estimate

Aug 6, 2026 · 04:27 PM ET· updated 3h ago

Share
Why It Matters

Organogenesis made less money per share than expected, but sold way more products than people thought it would. When a company sells a lot but doesn't make as much profit, it's worth watching to see if they can do better next time.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.